Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?
Tumor-infiltrating lymphocytes (TILs), frontline soldiers of the adaptive immune system, are recruited into the tumor site to fight against tumors. However, their small number and reduced activity limit their ability to overcome the tumor. Enhancement of TILs number and activity against tumors has b...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1018962/full |
| _version_ | 1828100102223298560 |
|---|---|
| author | Mohammad Hossein Kazemi Mohammad Hossein Kazemi Maryam Sadri Maryam Sadri Alireza Najafi Alireza Najafi Ali Rahimi Ali Rahimi Zeinab Baghernejadan Zeinab Baghernejadan Hossein Khorramdelazad Reza Falak Reza Falak |
| author_facet | Mohammad Hossein Kazemi Mohammad Hossein Kazemi Maryam Sadri Maryam Sadri Alireza Najafi Alireza Najafi Ali Rahimi Ali Rahimi Zeinab Baghernejadan Zeinab Baghernejadan Hossein Khorramdelazad Reza Falak Reza Falak |
| author_sort | Mohammad Hossein Kazemi |
| collection | DOAJ |
| description | Tumor-infiltrating lymphocytes (TILs), frontline soldiers of the adaptive immune system, are recruited into the tumor site to fight against tumors. However, their small number and reduced activity limit their ability to overcome the tumor. Enhancement of TILs number and activity against tumors has been of interest for a long time. A lack of knowledge about the tumor microenvironment (TME) has limited success in primary TIL therapies. Although the advent of engineered T cells has revolutionized the immunotherapy methods of hematologic cancers, the heterogeneity of solid tumors warrants the application of TILs with a wide range of specificity. Recent advances in understanding TME, immune exhaustion, and immune checkpoints have paved the way for TIL therapy regimens. Nowadays, TIL therapy has regained attention as a safe personalized immunotherapy, and currently, several clinical trials are evaluating the efficacy of TIL therapy in patients who have failed conventional immunotherapies. Gaining favorable outcomes following TIL therapy of patients with metastatic melanoma, cervical cancer, ovarian cancer, and breast cancer has raised hope in patients with refractory solid tumors, too. Nevertheless, TIL therapy procedures face several challenges, such as high cost, timely expansion, and technical challenges in selecting and activating the cells. Herein, we reviewed the recent advances in the TIL therapy of solid tumors and discussed the challenges and perspectives. |
| first_indexed | 2024-04-11T08:24:00Z |
| format | Article |
| id | doaj.art-e4ef941063d743fca69593ec4ee901a0 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T08:24:00Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-e4ef941063d743fca69593ec4ee901a02022-12-22T04:34:49ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-10-011310.3389/fimmu.2022.10189621018962Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?Mohammad Hossein Kazemi0Mohammad Hossein Kazemi1Maryam Sadri2Maryam Sadri3Alireza Najafi4Alireza Najafi5Ali Rahimi6Ali Rahimi7Zeinab Baghernejadan8Zeinab Baghernejadan9Hossein Khorramdelazad10Reza Falak11Reza Falak12Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, IranImmunology Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, IranDepartment of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, IranImmunology Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, IranDepartment of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, IranImmunology Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, IranDepartment of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, IranImmunology Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, IranDepartment of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, IranImmunology Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, IranDepartment of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, IranDepartment of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, IranImmunology Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, IranTumor-infiltrating lymphocytes (TILs), frontline soldiers of the adaptive immune system, are recruited into the tumor site to fight against tumors. However, their small number and reduced activity limit their ability to overcome the tumor. Enhancement of TILs number and activity against tumors has been of interest for a long time. A lack of knowledge about the tumor microenvironment (TME) has limited success in primary TIL therapies. Although the advent of engineered T cells has revolutionized the immunotherapy methods of hematologic cancers, the heterogeneity of solid tumors warrants the application of TILs with a wide range of specificity. Recent advances in understanding TME, immune exhaustion, and immune checkpoints have paved the way for TIL therapy regimens. Nowadays, TIL therapy has regained attention as a safe personalized immunotherapy, and currently, several clinical trials are evaluating the efficacy of TIL therapy in patients who have failed conventional immunotherapies. Gaining favorable outcomes following TIL therapy of patients with metastatic melanoma, cervical cancer, ovarian cancer, and breast cancer has raised hope in patients with refractory solid tumors, too. Nevertheless, TIL therapy procedures face several challenges, such as high cost, timely expansion, and technical challenges in selecting and activating the cells. Herein, we reviewed the recent advances in the TIL therapy of solid tumors and discussed the challenges and perspectives.https://www.frontiersin.org/articles/10.3389/fimmu.2022.1018962/fullcombination therapyimmunotherapysolid tumortumor-infiltrating lymphocyte (TIL)TIL therapy |
| spellingShingle | Mohammad Hossein Kazemi Mohammad Hossein Kazemi Maryam Sadri Maryam Sadri Alireza Najafi Alireza Najafi Ali Rahimi Ali Rahimi Zeinab Baghernejadan Zeinab Baghernejadan Hossein Khorramdelazad Reza Falak Reza Falak Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango? Frontiers in Immunology combination therapy immunotherapy solid tumor tumor-infiltrating lymphocyte (TIL) TIL therapy |
| title | Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango? |
| title_full | Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango? |
| title_fullStr | Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango? |
| title_full_unstemmed | Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango? |
| title_short | Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango? |
| title_sort | tumor infiltrating lymphocytes for treatment of solid tumors it takes two to tango |
| topic | combination therapy immunotherapy solid tumor tumor-infiltrating lymphocyte (TIL) TIL therapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1018962/full |
| work_keys_str_mv | AT mohammadhosseinkazemi tumorinfiltratinglymphocytesfortreatmentofsolidtumorsittakestwototango AT mohammadhosseinkazemi tumorinfiltratinglymphocytesfortreatmentofsolidtumorsittakestwototango AT maryamsadri tumorinfiltratinglymphocytesfortreatmentofsolidtumorsittakestwototango AT maryamsadri tumorinfiltratinglymphocytesfortreatmentofsolidtumorsittakestwototango AT alirezanajafi tumorinfiltratinglymphocytesfortreatmentofsolidtumorsittakestwototango AT alirezanajafi tumorinfiltratinglymphocytesfortreatmentofsolidtumorsittakestwototango AT alirahimi tumorinfiltratinglymphocytesfortreatmentofsolidtumorsittakestwototango AT alirahimi tumorinfiltratinglymphocytesfortreatmentofsolidtumorsittakestwototango AT zeinabbaghernejadan tumorinfiltratinglymphocytesfortreatmentofsolidtumorsittakestwototango AT zeinabbaghernejadan tumorinfiltratinglymphocytesfortreatmentofsolidtumorsittakestwototango AT hosseinkhorramdelazad tumorinfiltratinglymphocytesfortreatmentofsolidtumorsittakestwototango AT rezafalak tumorinfiltratinglymphocytesfortreatmentofsolidtumorsittakestwototango AT rezafalak tumorinfiltratinglymphocytesfortreatmentofsolidtumorsittakestwototango |